GENESKY
Genetic analysis services improving medical diagnostic accuracy
About GENESKY
Genesky, also known as 天昊基因, provides a range of molecular biology and gene detection research platforms. The company's services include next-generation sequencing, gene expression analysis, molecular cloning, and in situ hybridization, catering to various throughputs and applications.
The firm's gene analysis services cover genome and full transcriptome sequencing, detection of gene methylation, SNP typing, gene copy number detection, and metagenomic sequencing. These technologies are crucial for diagnostic testing, which can confirm or deny the presence of a suspected disorder by identifying genetic changes. By utilizing tools like next-generation sequencing, which analyzes the DNA sequence of small segments of the entire genome, Genesky can identify genetic variants that may be related to health and disease.
Source: Dealroom company dataAt a glance
- Founded
- 2014
- Headquarters
- China
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Sunland fund- PCPrinciple Capital
- SIShengyu Investment
Shenzhen Capital Group
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about GENESKY on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See GENESKY on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.